chloroquine has been researched along with Day Blindness in 45 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized double-blind study was performed to compare the side effects of long-term chemoprophylaxis of malaria with Fansidar (1 tablet a week) with those of a 300-mg weekly chloroquine regimen." | 5.05 | Tolerability of long-term prophylaxis with fansidar: a randomized double-blind study in Nigeria. ( Leimer, R; Stemberger, H; Wiedermann, G, 1984) |
| "Chloroquine and hydroxychloroquine effectively suppress rheumatoid arthritis with a superior benefit to risk ratio." | 5.05 | Antimalarial drugs for rheumatoid arthritis. ( Mackenzie, AH, 1983) |
| "Ophthalmic examinations and selected tests of visual function were performed on 64 patients with rheumatoid arthritis who had received daily doses of 200 mg chloroquine sulphate for periods ranging from 3 to 11 months." | 3.69 | Visual function and long-term chloroquine treatment. ( Anderson, IF; Bartel, PR; Becker, PJ; Brighton, SW; Robinson, E; Roux, P; van der Hoven, HJ, 1994) |
| "Numerous systemic drugs produce adverse effects that involve the eye." | 2.38 | Ocular side effects of selected systemic drugs. ( Jaanus, SD, 1992) |
| "Chloroquine-induced maculopathy may progress years after drug cessation and an apparent period of visual stability." | 1.46 | Delayed progression of bull's eye maculopathy. ( Jain, NG; Jain, S, 2017) |
| " Retinal toxicity may represent a rare adverse reaction to zoledronic acid, but this case suggests that caution should be used when administering this medication to patients with compromised retinal integrity." | 1.40 | Severe visual loss secondary to retinal toxicity after intravenous use of bisphosphonate in an eye with known chloroquine maculopathy. ( Bursztyn, LL; Masri, M; Sheidow, TG, 2014) |
| "Chloroquine maculopathy has a major impact on the vision-related health status of affected patients, emphasizing the need for its anticipation." | 1.39 | [Ophthalmologic screening history and vision-targeted health status of patients suffering from chloroquine maculopathy]. ( Bergholz, R; Joussen, AM; Rüther, K; Schroeter, J; Tillack, H, 2013) |
| " In patients in whom the daily dosage of hydroxychloroquine could be estimated (12 of 13), when using actual body weight, 8 were taking 6." | 1.37 | Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. ( Francis, PJ; Michaelides, M; Stover, NB; Weleber, RG, 2011) |
| "Serious visual impairment related to chloroquine rarely occurs if the daily dose does not exceed 250 mg." | 1.26 | Chloroquine retinopathy: is there a safe daily dose? ( Marks, JS, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (68.89) | 18.7374 |
| 1990's | 3 (6.67) | 18.2507 |
| 2000's | 2 (4.44) | 29.6817 |
| 2010's | 8 (17.78) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Handzel, DM | 1 |
| Romanou-Papadopoulou, V | 1 |
| Briesen, S | 1 |
| Jain, S | 1 |
| Jain, NG | 1 |
| Guiot, A | 1 |
| Couturier, M | 1 |
| Tebib, JG | 1 |
| Abouaf, L | 1 |
| Coury, F | 1 |
| Bursztyn, LL | 1 |
| Masri, M | 1 |
| Sheidow, TG | 1 |
| Tsang, AC | 1 |
| Ahmadi Pirshahid, S | 1 |
| Virgili, G | 1 |
| Gottlieb, CC | 1 |
| Hamilton, J | 1 |
| Coupland, SG | 1 |
| Marmor, MF | 1 |
| Kellner, U | 1 |
| Lai, TY | 1 |
| Melles, RB | 1 |
| Mieler, WF | 1 |
| Chiffoleau, A | 1 |
| Guillet, A | 1 |
| Zanlonghi, X | 1 |
| Jolliet, P | 1 |
| Michaelides, M | 1 |
| Stover, NB | 1 |
| Francis, PJ | 1 |
| Weleber, RG | 1 |
| Hickley, NM | 1 |
| Al-Maskari, A | 1 |
| McKibbin, M | 1 |
| Bergholz, R | 1 |
| Rüther, K | 1 |
| Tillack, H | 1 |
| Joussen, AM | 1 |
| Schroeter, J | 1 |
| Wozniacka, A | 1 |
| McCauliffe, DP | 1 |
| Wilson, W | 1 |
| Otto, W | 1 |
| Tautenhahn, B | 1 |
| David-Chaussé, J | 1 |
| Bessière, E | 1 |
| Vérin, P | 1 |
| Magendie, P | 1 |
| Reed, H | 1 |
| Karlinsky, W | 1 |
| Stemberger, H | 1 |
| Leimer, R | 1 |
| Wiedermann, G | 1 |
| Mackenzie, AH | 1 |
| Marks, JS | 1 |
| Glennås, A | 1 |
| Brath, HK | 1 |
| Bergaust, B | 1 |
| Feldmann, R | 1 |
| Salomon, D | 1 |
| Saurat, JH | 1 |
| Bartel, PR | 1 |
| Roux, P | 1 |
| Robinson, E | 1 |
| Anderson, IF | 1 |
| Brighton, SW | 1 |
| van der Hoven, HJ | 1 |
| Becker, PJ | 1 |
| Dubois, EL | 1 |
| Martin, LJ | 1 |
| Bergen, RL | 1 |
| Dobrow, HR | 1 |
| Dwivedi, GS | 1 |
| Mehra, YN | 1 |
| Tempe, JD | 1 |
| Jaeger, A | 1 |
| Beissel, J | 1 |
| Burg, F | 1 |
| Mantz, JM | 1 |
| Belghiti, J | 1 |
| Belghiti, D | 1 |
| Amedome, A | 1 |
| Durand, H | 1 |
| Frankel, EB | 1 |
| Jaanus, SD | 1 |
| Sammartino, JP | 1 |
| Soll, DB | 1 |
| Futenma, M | 1 |
| Branchevskaia, SIa | 1 |
| Jaros, Z | 1 |
| Bernstein, HN | 2 |
| Godel, V | 1 |
| Nemet, P | 1 |
| Stein, R | 1 |
| Zabel, R | 1 |
| Rinaldi, G | 1 |
| Coslovich, E | 1 |
| Tuvo, F | 1 |
| Pinckers, A | 1 |
| Meadows, SP | 1 |
| Simpson, GV | 1 |
| Percival, SP | 1 |
| Behrman, J | 1 |
| Motegi, T | 1 |
| Rothermich, NO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope[NCT04361318] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | ||
| A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults[NCT04370262] | Phase 3 | 233 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Posterior Segment Evaluation of Patients With Systemic Lupus Erythematosus Using Optical Coherence Tomography and Optical Coherence Tomography Angiography[NCT04866615] | 150 participants (Anticipated) | Observational | 2021-06-04 | Recruiting | |||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
7 reviews available for chloroquine and Day Blindness
| Article | Year |
|---|---|
Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test.
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Fluorescein Angiography; Humans; Hydroxychlo | 2015 |
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
Topics: Antimalarials; Chloroquine; Drug Interactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Cuta | 2005 |
Antimalarials in the management of discoid and systemic lupus erythematosus.
Topics: Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Humans; Lupus Erythematosus, | 1978 |
Ocular side effects of selected systemic drugs.
Topics: Amiodarone; Anti-Inflammatory Agents; Antirheumatic Agents; Chloroquine; Chlorpromazine; Drug Intera | 1992 |
[Effect of drugs on the eye].
Topics: Adrenal Cortex Hormones; Aminohippuric Acids; Antidepressive Agents; BCG Vaccine; Cardiac Glycosides | 1970 |
Some iatrogenic ocular diseases from systemically administered drugs.
Topics: Animals; Cataract; Cats; Chemical Phenomena; Chemistry; Chloramphenicol; Chloroquine; Chlorpromazine | 1970 |
Chloroquine ocular toxicity.
Topics: Animals; Binding Sites; Cataract; Cats; Chloroquine; Ciliary Body; Cornea; Electrooculography; Elect | 1967 |
2 trials available for chloroquine and Day Blindness
| Article | Year |
|---|---|
Tolerability of long-term prophylaxis with fansidar: a randomized double-blind study in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Blood Cell Count; Chloroquine; Clinical Trials as Topic; Double-Bl | 1984 |
Antimalarial drugs for rheumatoid arthritis.
Topics: Amodiaquine; Antimalarials; Arthritis, Rheumatoid; Body Weight; Chloroquine; Clinical Trials as Topi | 1983 |
36 other studies available for chloroquine and Day Blindness
| Article | Year |
|---|---|
[Visual loss under chloroquine treatment-and not (only) due to bull's eye maculopathy!]
Topics: Blindness; Chloroquine; Humans; Macular Degeneration; Vision Disorders | 2021 |
Delayed progression of bull's eye maculopathy.
Topics: Aftercare; Aged; Antirheumatic Agents; Chloroquine; Disease Progression; Electroretinography; Female | 2017 |
[Antimalarial drug retinopathy].
Topics: Adult; Antimalarials; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Lupus Erythemato | 2018 |
Severe visual loss secondary to retinal toxicity after intravenous use of bisphosphonate in an eye with known chloroquine maculopathy.
Topics: Antirheumatic Agents; Bone Density Conservation Agents; Chloroquine; Diphosphonates; Female; Humans; | 2014 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
[Antimalarial's retinopaty remains a current threat].
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Cohort Studies; Dose-Response Relationship, Drug; | 2009 |
Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Disease Progression; Drug Therapy | 2011 |
Chloroquine and hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Vis | 2011 |
[Ophthalmologic screening history and vision-targeted health status of patients suffering from chloroquine maculopathy].
Topics: Adult; Aged; Chloroquine; Health Status; Humans; Macula Lutea; Male; Mass Screening; Middle Aged; Ph | 2013 |
RETINOPATHY DURING CHLOROQUINE THERAPY.
Topics: Antirheumatic Agents; Blood Pressure; Chloroquine; Female; Humans; Liver Function Tests; Lupus Eryth | 1961 |
[Long-term chloroqine therapy of chronic rheumatic diseases].
Topics: Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Disability Evaluation; Gallbladder Diseases; Ga | 1966 |
[Results of ophthalmologic examination in 54 patients undergoing prolonged treatment with antimalarials].
Topics: Adult; Aged; Arthritis, Rheumatoid; Child; Chloroquine; Collagen Diseases; Eye Diseases; Female; Gen | 1967 |
Delayed onset of chloroquine retinopathy.
Topics: Adult; Chloroquine; Eye Diseases; Female; Fundus Oculi; Humans; Retina; Vision Disorders; Visual Fie | 1967 |
Chloroquine retinopathy: is there a safe daily dose?
Topics: Adolescent; Adult; Aged; Chloroquine; Drug Administration Schedule; Female; Humans; Male; Middle Age | 1982 |
[Ocular side effects of chloroquine treatment of rheumatoid arthritis patients].
Topics: Adult; Aged; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Male; Middle Aged; Vision Disorders | 1980 |
The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Topics: Adult; Aged; Chloroquine; Drug Combinations; Drug Tolerance; Female; Humans; Hydroxychloroquine; Lup | 1994 |
Visual function and long-term chloroquine treatment.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child; Chloroquine; Color Perception; Female; Humans | 1994 |
Delayed onset chloroquine retinopathy: case report.
Topics: Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Macula Lutea; Middle Aged; Retina; Re | 1978 |
Ototoxicity of chloroquine phosphate. A case report.
Topics: Chloroquine; Deafness; Humans; Male; Melanins; Middle Aged; Tinnitus; Vision Disorders | 1978 |
[Acute intoxications due to cardiotropic drugs : ajmaline, chloroquine and digitalin].
Topics: Acute Disease; Adolescent; Adult; Ajmaline; Chloroquine; Coma; Digitalis Glycosides; Female; Humans; | 1976 |
[Letter: Intoxication with chloroquine with cardiac disorders. Effect of isoprenaline].
Topics: Adolescent; Chloroquine; Heart Diseases; Humans; Hypotension; Isoproterenol; Male; Shock, Cardiogeni | 1975 |
Letter: Visual defect from chloroquine phosphate.
Topics: Chloroquine; Humans; Vision Disorders | 1975 |
Ocular toxicity of systemic drugs.
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Chloroquine; Contraceptives, Oral; Digitalis; Eye Di | 1985 |
Entero-Vioform and organic neurologic disease.
Topics: Arthritis, Rheumatoid; Chloroquine; Clioquinol; Diarrhea; Humans; Malaria; Optic Atrophy; Peripheral | 1971 |
[Chloroquine and ethambutol oculopathies in Japan].
Topics: Chloroquine; Ethambutol; Female; Humans; Japan; Male; Retinal Diseases; Vision Disorders | 1974 |
[Secondary toxic tapetoretinal dystrophy of the retina caused by delagil intoxication].
Topics: Adult; Chloroquine; Humans; Lupus Erythematosus, Systemic; Male; Retinal Degeneration; Retinal Disea | 1974 |
[Ocular involvement in chloroquine therapy].
Topics: Adult; Angiography; Chloroquine; Corneal Opacity; Dark Adaptation; Electroretinography; Eye Diseases | 1972 |
[Vision disorders and depigmentation of the hair of the head following on overdose of chloroquine diphosphate medication].
Topics: Child; Chloroquine; Hair; Humans; Male; Pigmentation Disorders; Skin Diseases; Vision Disorders | 1968 |
[On ocular damage caused by chloroquine].
Topics: Aged; Arthritis, Rheumatoid; Chloroquine; Color Vision Defects; Cornea; Eye Diseases; Female; Humans | 1971 |
[Eye disorders caused by chloroquine and hydroxychloroquine].
Topics: Adult; Chloroquine; Color Perception Tests; Electrooculography; Eye Manifestations; Female; Humans; | 1970 |
Visual failure and optic atrophy.
Topics: Adult; Amblyopia; Anemia, Pernicious; Child; Chloroquine; Craniocerebral Trauma; Cyanides; Female; H | 1970 |
Diagnosis and treatment of uveitis in association with sarcoidosis.
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Biopsy; Blood Protein Electrophoresis; Bone and Bones; | 1968 |
Ophthalmological safety of chloroquine.
Topics: Adult; Aged; Aging; Chloroquine; Electrooculography; Female; Fundus Oculi; Humans; Macula Lutea; Mal | 1969 |
Iatrogenic symptoms in ophthalmology.
Topics: Accommodation, Ocular; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; H | 1969 |
[Eye diseases induced by ethambutol].
Topics: Adult; Aged; Chloroquine; Ethambutol; Eye Diseases; Female; Humans; Iatrogenic Disease; Male; Middle | 1969 |
Visual impairment from antimalarial drug.
Topics: Chloroquine; Humans; Retina; Vision Disorders | 1966 |